Takip et
Anna Vildhede
Anna Vildhede
Senior scientist, AstraZeneca
alumni.chalmers.se üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug–drug interactions
M Karlgren, A Vildhede, U Norinder, JR Wisniewski, E Kimoto, Y Lai, ...
Journal of medicinal chemistry 55 (10), 4740-4763, 2012
3742012
In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes
JR Wiśniewski, A Vildhede, A Norén, P Artursson
Journal of proteomics 136, 234-247, 2016
1712016
Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions
A Vildhede, M Karlgren, EK Svedberg, JR Wisniewski, Y Lai, A Norén, ...
Drug metabolism and disposition 42 (7), 1210-1218, 2014
1262014
Comparative proteomic analysis of human liver tissue and isolated hepatocytes with a focus on proteins determining drug exposure
A Vildhede, JR Wisniewski, A Noren, M Karlgren, P Artursson
Journal of proteome research 14 (8), 3305-3314, 2015
1122015
Quantitative proteomics and mechanistic modeling of transporter‐mediated disposition in nonalcoholic fatty liver disease
A Vildhede, E Kimoto, RM Pelis, AD Rodrigues, MVS Varma
Clinical Pharmacology & Therapeutics 107 (5), 1128-1137, 2020
602020
Mechanistic modeling of pitavastatin disposition in sandwich-cultured human hepatocytes: a proteomics-informed bottom-up approach
A Vildhede, A Mateus, EK Khan, Y Lai, M Karlgren, P Artursson, ...
Drug Metabolism and Disposition 44 (4), 505-516, 2016
512016
Primary human hepatocyte spheroid model as a 3D in vitro platform for metabolism studies
KP Kanebratt, A Janefeldt, L Vilén, A Vildhede, K Samuelsson, L Milton, ...
Journal of Pharmaceutical Sciences 110 (1), 422-431, 2021
442021
Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes
Y Bi, RJ Scialis, S Lazzaro, S Mathialagan, E Kimoto, J Keefer, H Zhang, ...
The AAPS journal 19, 787-796, 2017
432017
Organic anion transporter 2 mediates hepatic uptake of tolbutamide, a CYP2C9 probe drug
Y Bi, S Mathialagan, L Tylaska, M Fu, J Keefer, A Vildhede, C Costales, ...
Journal of Pharmacology and Experimental Therapeutics 364 (3), 390-398, 2018
382018
Comparison of proteomic quantification approaches for hepatic drug transporters: multiplexed global quantitation correlates with targeted proteomic quantitation
A Vildhede, C Nguyen, BK Erickson, RC Kunz, R Jones, E Kimoto, ...
Drug Metabolism and Disposition 46 (5), 692-696, 2018
282018
Quantification of hepatic organic anion transport proteins OAT2 and OAT7 in human liver tissue and primary hepatocytes
A Vildhede, E Kimoto, AD Rodrigues, MVS Varma
Molecular pharmaceutics 15 (8), 3227-3235, 2018
222018
In vitro studies with two human organic anion transporters: OAT2 and OAT7
S Mathialagan, C Costales, L Tylaska, E Kimoto, A Vildhede, J Johnson, ...
Xenobiotica 48 (10), 1037-1049, 2018
202018
Transporter-mediated disposition, clinical pharmacokinetics and cholestatic potential of glyburide and its primary active metabolites
R Li, Y Bi, A Vildhede, RJ Scialis, S Mathialagan, X Yang, LD Marroquin, ...
Drug Metabolism and Disposition 45 (7), 737-747, 2017
132017
Gene-by-environment interaction of Bcrp−/− and methionine-and choline-deficient diet–induced nonalcoholic steatohepatitis alters SN-38 disposition
EL Toth, H Li, AL Dzierlenga, JD Clarke, A Vildhede, M Goedken, ...
Drug Metabolism and Disposition 46 (11), 1478-1486, 2018
82018
Hepatocyte size fractionation allows dissection of human liver zonation
M Ölander, C Wegler, I Flörkemeier, A Treyer, N Handin, JM Pedersen, ...
Journal of Cellular Physiology 236 (8), 5885-5894, 2021
72021
Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction
L Prieto Garcia, A Lundahl, C Ahlström, A Vildhede, H Lennernäs, ...
CPT: Pharmacometrics & Systems Pharmacology 11 (9), 1194-1209, 2022
52022
Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling
J Dong, L Prieto Garcia, Y Huang, W Tang, A Lundahl, M Elebring, ...
Clinical Pharmacology & Therapeutics 114 (4), 825-835, 2023
42023
In vitro assessment of the drug–drug interaction potential of verinurad and its metabolites as substrates and inhibitors of metabolizing enzymes and drug transporters
VS Gopaul, A Vildhede, TB Andersson, F Erlandsson, CA Lee, ...
Journal of Pharmacology and Experimental Therapeutics 378 (2), 108-123, 2021
32021
Characterization of bile acid sulfate conjugates as substrates of human organic anion transporting polypeptides
CC Orozco, M Neuvonen, YA Bi, MA Cerny, S Mathialagan, L Tylaska, ...
Molecular Pharmaceutics 20 (6), 3020-3032, 2023
22023
Global proteome changes in liver tissue 6 weeks after FOLFOX treatment of colorectal cancer liver metastases
J Urdzik, A Vildhede, JR Wiśniewski, F Duraj, U Haglund, P Artursson, ...
Proteomes 4 (4), 30, 2016
22016
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20